Genocea

📍 Cambridge, United States🗓 Founded 2006👥 92 employees💰 Last funded 2017
Biotechnology🌐 genocea.com
Website LinkedIn
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
5
Total investors
1
Early stage
1
Mid stage
1
Late stage
2006
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
France
1
Investor activity2006–2017 · investors recorded per year
2006120101201312016120171
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Genocea?
Genocea has 5 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 1 late-stage investors.
When did Genocea last raise funding?
The most recent investment in Genocea recorded on gritt.io was in 2017.
When was Genocea founded?
Genocea was founded in 2006.
What industry is Genocea in?
Genocea operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Genocea based?
Genocea is headquartered in Cambridge, United States.